Informed consent statement: Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.
INTRODUCTION
Endoscopic resection (ER) including endoscopic mucosal resection and endoscopic submucosal dissection (ESD) is a recognized as one of treatment options for curative resection of early gastric cancer (EGC) without simultaneous concomitant lymph node metastasis [1] [2] [3] [4] . Unlike surgery of EGC, ER preserves most part of the stomach and this leads to increased risk of metachronous gastric cancer (MGC) development in residual gastric mucosa [5] . As more EGCs are treated with ER recently, identifying risk factors of MGC development after ER of EGC is important.
Helicobacter pylori (H. pylori) infection is related to the development of gastritis, atrophy, intestinal metaplasia, dysplasia, and gastric cancer [6] [7] [8] [9] . Among dietary, environmental, and genetic risk factors of gastric cancer, H. pylori is classified as a Group 1 or definite carcinogen for gastric cancer by the World Health Organization [10] . In previous reports, the odds for development of gastric cancer reported to increase by 2-4 folds in the patients with H. pylori infection [11, 12] . The effect of H. pylori eradication on development of MGC after ER of EGC is still on debate. A study of 132 patients who underwent ER for EGC and showed positive H. pylori serologic test demonstrated that H. pylori eradication inhibited the growth of new gastric cancer [13] and a retrospective study of 283 patients with H. pylori infection at time of ESD for EGC showed that failure of H. pylori eradication was a risk factor of MGC development [5] . However, a study of 1258 patients who underwent ESD for EGC reported that the incidence rate of MGC was not significantly different between patients with or without H. pylori eradication [14] and a retrospective study of 268 patients with a 5-year followup reported that H. pylori eradication after ER for EGC did not significantly reduced the incidence of MGC [15] . Studies about the effect of H. pylori status test on development of MGC after ER of EGC has been scarce.
The aims of this study were to investigate the effect of H. pylori status test and H. pylori eradication on the occurrence of MGC after ESD of EGC and risk factors of MGC.
MATERIALS AND METHODS

Patients
The medical records of 599 patients with 611 lesions who underwent ESD for EGC from January 2005 to January 2015 at Yeungnam university hospital were retrospectively reviewed. Exclusion criteria of the present study were as follows: additional gastrectomy due to a non-curative ESD of EGC and short-term follow-up duration (< 6 mo) and a total of 166 patients with 170 lesions were excluded from the present study. Finally, 433 patients with 441 lesions were included for analysis. Baseline clinical characteristics of the patients, characteristics and histology findings of EGC, performance of H. pylori status test and H. pylori eradication and occurrence of MGC were analyzed. Institutional review board approval was obtained for this study (2016-06-035).
H. pylori status and follow-up
Patients were divided into two groups; the H. pylori tested group (n = 257) and the H. pylori non-tested group (n = 176) based on performance of H. pylori status test after ESD of EGC. Patients in the H. pylori tested group were further divided into three subgroups; the H. pylori negative subgroup, the H. pylori eradicated subgroup, and the H. pylori persistent subgroup ( Figure  1 ).
Among patients with positive H. pylori test results, patients who agreed to treat H. pylori infection received H. pylori eradication. The regimen for first-line H. pylori treatment was triple therapy with amoxicillin 1000 mg, clarithromycin 500 mg, and a protonpump inhibitor (pantoprazole 40 mg, eomeprazole  40 mg, lansoprazole 30 mg or rabeprazole 20 mg) all twice daily for a week. The regimen for secondline H. pylori treatment was a quadruple therapy with metronidazole 500 mg (3 times daily), tetracycline 500 mg (4 times daily), tripotassium dicitrato bismuthate 300 mg (4 times daily), and a proton-pump inhibitor (twice daily) for 10-14 d. Eradication was confirmed by histology or rapid urase test at scheduled esophagogastroduodenoscopy (EGD) follow-up after ESD or urea breathing test. After ESD, scheduled EGD was performed at 2 or 3, 6, and 12 mo, and annually thereafter.
The presence of gastric mucosal atrophy was assessed through EGD and presence of intestinal metaplasia through histology. MGC was defined as the development of new gastric cancer at a previously uninvolved site in the stomach after the 6 mo following ESD. MGC was confirmed by histology of biopsy specimens. Incidences of MGC was compared according to performance of H. pylori status test and among the H. pylori eradicated, persistent and negative group and risk factors of MGC were analyzed.
Statistical analysis
Results are presented as means and standard deviations or as medians and ranges. The χ 2 or Fisher's exact test and one-way analysis of variance test or the Student's t-test were used to compare categorical and continuous variables, respectively. The log-rank test was used for to compare group incidence rates. Univariate and multivariate Cox proportional hazard regression analyses were used to identify independent risk factors associated with MGC development. Covariates with P values of < 0.05 by univariate analyses were entered into multivariate analysis. Statistical analyses of the data were performed using SPSS 20 (IBM SPSS, Chicago, IL, United States). Statistical significance was accepted for P values < 0.05. Figure 1 ). The mean age of H. pylori tested group was 66.61 years and 189 (73.5%) patients were male. Patients in the H. pylorieradicated subgroup were significantly younger than patients in the H. pylori-negative and H. pyloripersistent subgroups (P < 0.05). The mean followup duration was not significantly different between three subgroups (P > 0.05). Endoscopic mucosal atrophy and intestinal metaplasia were significantly more prevalent in the H. pylori-negative subgroup than the other two subgroups (P < 0.05). The location and macroscopic type of primary gastric cancer were not significantly different between three subgroups (P > 0.05). The H. pylori-persistent subgroup had significantly less differentiated cancers than other two subgroups (P = 0.032) ( Table 1) .
RESULTS
Baseline characteristics of the patients
The mean age and follow-up duration were not 
Characteristics of patients with MGC
Mean age of patients with MGC was 68.93 years and all patients with MGC were male. No significant differences were observed between MGC group and non-MGC group in terms of age, primary cancer location, and primary lesion size (P > 0.05), and mean follow-up duration was not significantly different between two groups (P = 0.752). Endoscopic mucosal atrophy and intestinal metaplasia were significantly more prevalent in patients with MGC than without (P < 0.05) ( Table 3 ).
In the H. pylori tested group, age, primary cancer location, and lesion size were not significantly different between patients with or without MGC and follow-up duration was similar between two groups (33.72 ± 23.64 vs 34.13 ± 25.30, P = 0.997). The patient with MGC showed higher proportion of negative H. pylori status than without (63.6% vs 35.8%, P = 0.061). However, endoscopic mucosal atrophy and intestinal metaplasia were observed significantly more in patients with MGC than without (72.7% vs 30.5%, P = 0.003 and 81.8% vs 42.3%, P = 0.010) ( Table 4) .
Factors associated with the development of MGC
In the H. pylori test group, endoscopic mucosal atrophy and intestinal metaplasia were found to be significantly associated with the development of MGC by univariate analysis (P < 0.05). Multivariate Cox proportional significantly different between the H. pylori tested and the H. pylori non-tested groups (P > 0.05). Endoscopic mucosal atrophy and intestinal metaplasia was significantly more frequent in the H. pylori tested group than in the H. pylori non-tested group, and location of primary gastric cancer location was significantly lower in the H. pylori tested group than the H. pylori nontested group (P < 0.05). In addition, the H. pylori nontested group had more elevated lesions than the H. pylori tested group and the H. pylori tested group had more depressed lesions than the H. pylori non-tested group (P < 0.05) ( Table 2 ).
Development of MGC according to H. pylori status
Among total 433 patients, MGC developed in 15 (3.5%) patients; 11 (4.3%) patients in the H. pylori tested group and 4 (2.3%) in the H. pylori non-tested group without significant difference (P = 0.262) ( Table 2) .
Among 11 patients who developed MGC in the H. pylori tested group, MGC developed in 7 (7.4%) patients of the H. pylori-negative subgroup, 3 (2.5%) patients of the H. pylori-eradicated subgroup, and 1 (2.4%) patient of the H. pylori-persistent subgroup. Although the incidence of MGC was higher in the H. pylori-negative subgroup than other two subgroups, statistical significance was not found among the three subgroups (P = 0.173) ( Table 1) . hazard regression analysis revealed an association with MGC development only for endoscopic mucosal atrophy (HR = 6.080, P = 0.009) ( Table 5) . In all patients, endoscopic mucosal atrophy and intestinal metaplasia were significantly associated with MGC development in univariate analysis and multivariate Cox proportional hazard regression analysis showed an association between intestinal metaplasia and MGC development (HR = 4.67, P = 0.006) ( Table 6 ).
DISCUSSION
In the present study, 15 (3.5%) of the 433 patients developed MGC after ESD for EGC and this result was comparable with previous reports [16, 17] . MGC occurs more frequently after ER for EGC than surgery (2.5%-14% vs 1.8%-5%) [16] [17] [18] [19] . This increased risk of MGC after ER for EGC can be partly explained by higher proportion of salvaged stomach in ER than surgery. The mean duration of MGC development from ESD of EGC was 35.6 mo and 3 patients developed MGC after 5 years from initial ESD of EGC. A retrospective study of 1526 patients who underwent ESD for EGC reported that 5-year, 7-year, and 10-year cumulative incidence functions of MGC were 9.5%, 13.1%, and 22.7%, respectively [20] . Meticulous examination at surveillance EGD is needed in patients who underwent ER for EGC and EGD should be done with schedule.
Further studies are needed to find optimal schedule for surveillance EGD after ER of EGC.
The chronic inflammation of stomach induced by H. pylori infection may lead to mucosal atrophy, intestinal metaplasia, and dysplasia, and risk of developing gastric cancer is increased in patients exhibiting such histologic changes of stomach [21, 22] . An animal study has reported that H. pylori eradication decreased polyp formation, inflammatory cell infiltration, and cellular proliferation in the gastric mucosa and suggested that H. pylori eradication could diminish mucosal alterations related to gastric carcinogenesis [23] . However, the The mucosal atrophy of stomach has been previously reported to contribute to the development of MGC [15] . A study of 100 patients who underwent ESD for EGC reported that the frequency of severe atrophy assessed by histology was higher in the group that developed cancer compared to the group that did not and severity of atrophy was the only independent risk factor of MGC development after H. pylori eradication [24] . In the present study, endoscopic mucosal atrophy and intestinal metaplasia were observed more frequently in patients with MGC than in those without. Furthermore, multivariate analysis showed that endoscopic mucosal atrophy in the H. pylori tested group and intestinal metaplasia in all patients as a risk factor of MGC development after ESD of EGC.
The effect of H. pylori eradication on improvement of mucosal atrophy remains unclear in previous studies [25] [26] [27] [28] . A study of 544 patients with EGC reported the preventive effect of H. pylori eradication on development of MGC after ER of EGC even in patients with corpus atrophy [29] . However, a largescale, randomized, and controlled study about 1630 healthy carriers of H. pylori infection in China reported that the H. pylori carriers with precancerous state defined as presence of mucosal atrophy, intestinal metaplasia, or dysplasia had no preventive effect of H. pylori eradication on development of gastric cancer [30] . The ineffectiveness of H. pylori eradication on MGC development after ESD of EGC in the present study might have been due to irreversible mucosal atrophic change. Further studies to clarify the effect of H. pylori eradication on MGC development according to status of gastric mucosa is needed.
In the present study, all patients who developed MGC were male. A previous study reported that male gender was one of risk factors for MGC development of ESD of EGC [20] . However, male gender was not found as a risk factor of MGC in the present study and further study with longer follow up duration is needed to clarify the effect of gender on development of MGC after ESD of EGC. The present study has several limitations. First, its retrospective nature study makes selection bias inevitable, as was reflected by differences in the baseline characteristics of patients including atrophy and intestinal metaplasia status. Second, relatively small patients of MGC were included for the analysis, and if more patients with MGC had been included, it is possible that H. pylori eradication might have been found to influence MGC development. Third, determination of H. pylori infection status was inadequate, and thus, false negative and positive results were possibly included. Forth, we did not examine other causes of mucosal atrophy.
In conclusion, H. pylori eradication and H. pylori status test seems to have no preventive effect on the development of MGC after ESD for EGC. The risk factors of MGC development after ESD of EGC were gastric mucosal atrophy in H. pylori tested group and intestinal metaplasia in all patients.
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